Table 2

Demographic and baseline characteristics of patients in RA-BEAM (MTX-IR patients with established RA) and RA-BEGIN (csDMARD-naïve patients with early RA) stratified by averaged hsCRP

RA-BEAMRA-BEGIN
hsCRP ≤5 mg/LhsCRP >5 mg/LhsCRP ≤5 mg/LhsCRP >5 mg/L
PBO (n=63)Bari 4 mg (n=262)ADA (n=158)PBO (n=257)Bari 4 mg (n=149)ADA (n=107)MTX (n=56)Bari 4 mg (n=73)Bari 4 mg ± MTX (n=120)MTX (n=81)Bari 4 mg (n=54)Bari 4 mg ± MTX (n=47)
Age, years52.9±10.653.2±12.252.3±12.652.9±12.052.2±12.253.2±11.149.8±12.551.4±12.547.7±14.450.7±14.047.7±11.449.5±13.3
Female, n (%)50 (79.4)202 (77.1)121 (76.6)202 (78.6)113 (75.8)78 (72.9)41 (73.2)53 (72.6)89 (74.2)55 (67.9)44 (81.5)34 (72.3)
BMI, kg/m2 26.2±5.125.6±5.225.3±4.527.3±6.829.0±6.528.1±5.924.9±4.426.0±5.925.1±5.628.1±7.327.5±7.229.0±5.6
Smoker, yes, n (%)13 (20.6)56 (21.4)28 (17.7)54 (21.0)36 (24.2)30 (28.0)6 (10.7)15 (20.5)30 (25.0)20 (24.7)16 (29.6)6 (12.8)
Duration of RA from diagnosis, years7.6±7.08.4±8.16.9±6.69.2±7.88.9±9.310.0±9.30.8±1.92.0±4.41.0±2.11.2±3.81.2±2.62.3±4.1
hsCRP, mg/L6.3±5.917.9±18.617.0±16.220.1±18.330.1±26.826.5±21.814.8±13.919.2±17.917.5±18.627.0±22.024.6±21.443.3±39.1
HAQ-DI1.4±0.71.4±0.71.5±0.71.5±0.71.8±0.71.7±0.71.5±0.71.6±0.81.5±0.71.7±0.71.6±0.71.9±0.7
RF-positive*, n (%)57 (90.5)238 (90.8)144 (91.1)238 (92.6)134 (89.9)99 (92.5)56 (100)73 (100)113 (94.2)76 (93.8)53 (98.1)45 (95.7)
ACPA-positive†, n (%)53 (84.1)233 (88.9)141 (89.2)223 (86.8)133 (89.3)96 (89.7)53 (94.6)67 (91.8)110 (91.7)74 (91.4)49 (90.7)42 (89.4)
Pain assessment55.2±22.160.0±21.757.7±22.158.8±22.163.6±22.262.9±24.360.4±25.062.0±23.361.4±23.967.1±24.260.9±20.769.5±15.3
mTSS34.4±43.243.4±50.141.4±47.544.7±50.240.5±51.649.5±58.511.4±24.510.3±20.111.4±20.711.0±14.212.9±29.913.2±21.8
  • Data are mean±SD or n (%).

  • Averaged hsCRP in RA-BEAM calculated as the mean of postbaseline measurements at weeks 4, 12, 16, 20 and 24 and in RA-BEGIN as the mean of postbaseline measurements at weeks 4, 12, 16, 20, 24, 32, 40 and 52.

  • *RF-positive >14 units/mL (ULN).

  • †ACPA-positive >10 units/mL (ULN).

  • ACPA, anticyclic citrullinated peptide antibody; ADA, adalimumab; Bari, baricitinib; BMI, body mass index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; HAQ-DI, Health Assessment Questionnaire-Disability Index; hsCRP, high-sensitivity C reactive protein; mITT, modified intent-to-treat; mTSS, modified Total Sharp Score; MTX-IR, inadequate response to methotrexate; n, number of mITT completers; PBO, placebo; RA, rheumatoid arthritis; RF, rheumatoid factor; ULN, upper limit of normal.